Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

Recruiting patients for conditions like NASH—where individuals often remain asymptomatic and unaware of their diagnosis—presents unique obstacles. As Dan Peres of Immuron explains, many patients discover fatty liver only incidentally through imaging, and without symptoms or approved treatments, neither physicians nor patients actively seek diagnosis, limiting trial opportunities. Social media campaigns failed to yield meaningful results due to low patient awareness and engagement. To overcome these hurdles, Immuron shifted its approach from traditional hepatology specialties to non‑hepatology settings—such as endocrinology clinics treating diabetic patients—to teach clinical staff how to identify high‑risk individuals and refer them for confirmatory liver biopsy screening, effectively broadening the recruitment funnel and improving detection performance beyond specialized hepatologists.

Clinical Leader: How Do You Recruit Patients Unaware Of Their Disease?